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a case of Minimal change Disease treated successfully with 
Mycophenolate Mofetil in a patient with systemic Lupus 
erythematosus 
Young Hoon Hong, Dae Young Yun, Yong Wook Jung, Myung Jin oh, Hyun Je Kim, and choong Ki Lee
Department of Internal Medicine, Yeungnam University College of Medicine, Daegu, Korea 
The World Health Organization classifies lupus nephritis as class I to V or VI. However, a few cases of minimal change 
glomerulopathy have been reported in association with systemic lupus erythematosus (SLE). Mycophenolate mofetil has 
been shown to be effective for treatment of minimal change disease and lupus nephritis. A 24-year-old woman diagnosed 
with SLE five years prior to presentation complained of a mild generalized edema. The urinalysis showed microscopic 
hematuria and proteinuria. The assessed amount of total proteinuria was 1,618 mg/24 hours. A renal biopsy demonstrated 
diffuse fusion of the foot processes of podocytes on electron microscopy. Mycophenolate mofetil was started in addition 
to the maintenance medications of prednisolone 10 mg/day and hydroxychloroquine 400 mg/day. After six months of 
treatment, the microscopic hematuria and proteinuria resolved, and the total urine protein decreased to 100 mg/24 hours. 
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INTRODUCTION
Mycophenolate mofetil (MMF) has been reported to be 
effective in the treatment of minimal change disease and 
lupus nephritis. However, there is no consensus on its use 
for minimal change disease especially in systemic lupus 
erythematosus (SLE).
CASE REPORT
A 24-year-old woman diagnosed with SLE five years 
previously and maintained on prednisolone 5 mg/day and 
hydroxychloroquine 400 mg/day complained of mild gen-
eralized edema. 
At the time of the diagnosis of SLE, the patient was re-
ferred to the emergency room for cough, sputum produc-
tion and bruising. Severe thrombocytopenia was associ-
ated with oral ulcerations, arthritis, high titer speckled 
fluorescent antinuclear antibody test (FANA), ds-DNA Ab, 
anti-Smith Ab, positive Venereal Disease Research Labo-
ratory (VDRL) and normal bone marrow cellularity and 
maturity. These abnormalities normalized after treatment 
with intravenous immunoglobulin (IVIG) 400 mg/kg for 
five days, prednisolone 60 mg/day and hydroxychloro-
quine 400 mg/day. 
In order to evaluate the newly developed generalized 
edema, the patient had a 24 hours urine test for total 
protein and a duplex scan for renal vascular patency and 
blood flow. The white blood cell (WBC) count was 4,800/
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μL, Hgb 13 g/dL, platelet 279,000/μL, aspartate amino-
transferase/alanine aminotransferase (AST/ALT) 44/15 
U/L, and blood urea nitrogen/creatinine (BUN/Cr) 9.8/0.6 
mg/dL on blood testing. The urinalysis demonstrated 2 
(++) proteinuria on albustick, and the total urine protein 
was 1,618 mg/24 hr. The duplex scan showed patent renal 
vasculature and normal flow. 
To evaluate the glomerular proteinuria in this patient 
with SLE a renal biopsy was performed. On light micros-
copy, no abnormalities were found; immunofluorescent 
staining showed normal findings (Fig. 1). However, elec-
tron microscopy revealed diffuse fusion and microvilli 
formation of the foot processes, no electron dense material 
in the mesangium, electrolucent and absorptive features 
of epimembranous deposits and tubulo-reticular bodies in 
the endothelial cell cytoplasm (Fig. 2). These findings were 
compatible with a podocytopathy. With no other possible 
causes for the glomerular podocytopathy the patient was 
diagnosed as minimal change disease associated with ac-
tive SLE presenting with glomerular proteinuria and gen-
eralized edema. 
To control minimal change disease, high-dose gluco-
corticoid therapy remains the mainstay. But because the 
patient had experienced glucocorticoid-related adverse ef-
fects such as severe edema, weight gain, gastro-intestinal 
Figure 1. Kidney biopsy. No specific pathology was found on 
light microscopy (Periodic acid-Schiff stain, ×200).
Figure 2. Kidney biopsy. The electron microscopy showed dif-
fuse fusion of the foot processes, microvilli formation of foot 
processes, no electron dense material in the mesangium, electro-
lucent and absorptive features of epimembranous deposits and 
tubulo-reticular bodies in the endothelial cell cytoplasm (Uranyl 
acetate and lead citrate double stain; A: × 2,000; B, C: × 5,000).
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disturbances and dermatopathy previously, prednisolone 
10 mg/day and MMF, escalating up to 2.0 g/day, were 
added to the maintenance medications. The urine protein 
after three months of treatment decreased to 1 (+) on the 
albustick, and the 24 hours total urine protein was 945 
mg. After six months, the WBC count was 7,350/μL, Hgb 
12.9 g/dL, platelet 250,000/uL, AST/ALT 36/10 U/L, se-
rum total protein 7.2 g/dL, serum albumin 3.8 g/dL, and 
BUN/Cr 10.5/0.7 mg/dL. The 24-hour total urine protein 
was 100 mg and the symptoms of generalized edema had 
resolved.
DISCUSSION
SLE is a prototype autoimmune disease involving mul-
tiple organs. Despite the potential to cause pathology in 
any organ, renal involvement in particular is known to be 
associated with active disease and is considered a major 
prognostic factor in patients with SLE. 
Lupus nephritis is classified according to the World 
Health Organization consensus into class I to V or VI dis-
ease [1]. Glomerulonephritis is considered the result of im-
mune injury mediated by lymphocytes. Anti-glomerular 
antibody formation, immune complex deposition on the 
basement membrane and anti-neutrophil cytoplasmic an-
tibody activating neutrophils injure the glomerulus alone 
or in conjunction with autoantibodies and are important 
in the pathogenesis of this disease. 
Minimal change disease is characterized by absence 
of abnormalities on light microscopy and absence of im-
munoglobulin deposits, in the glomerulus, on immuno-
fluorescent staining. The differential diagnosis of these 
findings includes a malignancy such as Hodgkin’s disease 
or drug toxicity such as non-steroidal anti-inflammatory 
drugs (NSAIDs) in adults. Only a few cases of minimal 
change disease have been reported to be associated with 
SLE [2,3]. 
In the setting of overproduction of autoantibodies and 
immune complexes, the pathogenesis of non-immune 
minimal change disease remains to be elucidated. Makino   
et al. [4] reported a case of minimal change nephritic syn-
drome associated with SLE and treated with methylpred-
nisolone pulse therapy. Dube et al. [5] reported on seven 
patients with SLE and minimal change disease treated 
with prednisone and cessation of NSAIDs. Kraft et al. [6] 
reviewed glomerular podocytopathy in SLE patients with 
normal glomeruli by light microscopy, mesangial prolif-
erative glomerulonephritis and focal segmental glomeru-
losclerosis (FSGS) on renal biopsy and concluded that the 
podocytopathy was the result of active lupus, rather than 
coexistence of two separate but concurrent diseases, SLE 
and minimal change glomerulopathy. Treatment of lupus 
nephritis requires aggressive therapy to reverse and pre-
vent renal function from deteriorating to chronic kidney 
disease, especially in patients with class III and IV prolif-
erative glomerulopathies where high dose glucocorticoids 
and immunosuppressants, such as cyclophosphamide 
and cyclosporine, are the standard treatments. Minimal 
change disease in adults is more likely to be resistant; 
patients are dependent on glucocorticoid treatment alone 
or combined with immunosuppressant therapy. However, 
even with adequate treatment, relapses are common.
Recently, MMF has been introduced as a promising 
therapeutic agent for the treatment of idiopathic nephritic 
syndrome even in cases of primary refractory nephritic 
syndrome [7]. Zhao et al. [8] reported that MMF was an 
effective and well tolerated immunosuppressive agent for 
patients with refractory nephritic syndrome in a prospec-
tive multicenter clinical observational study of 19 cases of 
refractory nephrotic minimal change disease and prolif-
erative glomerulonephritis. Pesavento et al. [9] described 
the use of MMF in a case of frequently relapsing minimal 
change disease treated with cyclophosphamide therapy. 
Choi et al. [10] reported that empirical MMF therapy in the 
majority of patients with primary glomerulopathies was 
well tolerated. The treated patients achieved the goals of 
steroid withdrawal, improvement of nephrotic syndrome 
and stabilization of renal function in forty-six patients 
with biopsy proven primary glomerulopathies on MMF 
for more than three months. MMF can be a treatment 
alternative to the standard cyclophosphamide regimes in 
refractory cases. However, there are currently no consen-
sus guidelines for MMF treatment of lupus nephritis and 
minimal change disease, especially where it is associated 
with SLE. We successfully treated a patient who presented 
with minimal change disease of non-nephrotic range pro-
teinuria in SLE with MMF.
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